PetMed Express, Inc. (PETS)
NASDAQ: PETS · Real-Time Price · USD
2.570
-0.090 (-3.38%)
Oct 28, 2025, 4:00 PM EDT - Market closed
PetMed Express Revenue
In the fiscal year ending March 31, 2025, PetMed Express had annual revenue of $226.97M, down -17.19%. PetMed Express had revenue of $46.47M in the quarter ending March 31, 2025, a decrease of -21.95%.
Revenue (ttm)
$226.97M
Revenue Growth
-17.19%
P/S Ratio
0.24
Revenue / Employee
$1,311,977
Employees
173
Market Cap
53.96M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 226.97M | -47.12M | -17.19% |
| Mar 31, 2024 | 274.10M | 26.53M | 10.71% |
| Mar 31, 2023 | 247.57M | -24.71M | -9.08% |
| Mar 31, 2022 | 272.28M | -31.30M | -10.31% |
| Mar 31, 2021 | 303.58M | 19.46M | 6.85% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
PETS News
- 8 days ago - PetMed Express, Inc. Appoints Former Deloitte Partner James LaCamp as Director and Audit Committee Chair - GlobeNewsWire
- 13 days ago - PETMED REMINDER: Bragar Eagel & Squire, P.C. Reminds PetMed Express Investors of the Ongoing Investigation on Behalf of Stockholders - GlobeNewsWire
- 14 days ago - PetMeds® Files Form 10-K for Fiscal 2025 - GlobeNewsWire
- 15 days ago - PetMed Express (PETS) Faces Investor Scrutiny Amid Filing Delays, Executive Departures, Admitted Accounting Rule Violations -- Hagens Berman - GlobeNewsWire
- 20 days ago - PetMed Express, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - PetMed Express, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewsWire
- 2 months ago - PetMed Express, Inc. Announces Management Changes - GlobeNewsWire
- 4 months ago - PetMed Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K - GlobeNewsWire